K/DOQI [7] guidelines recommend that patients with severe hyperparathyroidism (persistent serum levels of intact PTH >800 pg/mL [88.0 pmol/L]), accompanied with hypercalcemia and/or hyperphosphatemia refractory to medical therapy should receive PTX. This evidence concerns the gene PTH and hypercalcemia disease.